["{\"step_by_step_thinking\": \"The provided documents discuss experimental therapies for multiple sclerosis, including azathiaprine therapy which was studied in a group of 13 patients. The study found that azathiaprine therapy did not significantly change the titre of antimyelin antibody. Additionally, the article on new approaches to the therapy of demyelinating disease mentions the application of advances in molecular and cellular immunology, but does not specifically mention ofatumumab. Therefore, there is no conclusive evidence to support or refute the effectiveness of ofatumumab for multiple sclerosis.\", \"answer_choice\": B}"]